The Phase 2 trial is a single-arm investigation designed to evaluate safety, survival, and immune response in patients treated with an autologous tumor-derived heat shock protein peptide-complex (HSPPC-96) administered at 25 μg per dose injected intradermally once weekly for 4 consecutive weeks and monthly following standard treatment with radiation and temozolomide.